ALX Oncology (NASDAQ:ALXO - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.
ALX Oncology Trading Down 1.8%
Shares of ALX Oncology stock traded down $0.03 during trading on Friday, hitting $1.72. The stock had a trading volume of 401,818 shares, compared to its average volume of 820,039. The firm's fifty day simple moving average is $1.39 and its 200-day simple moving average is $0.82. The stock has a market cap of $92.05 million, a PE ratio of -0.78 and a beta of 1.21. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.52 and a quick ratio of 4.52. ALX Oncology has a 12 month low of $0.40 and a 12 month high of $2.27.
ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). As a group, sell-side analysts expect that ALX Oncology will post -2.76 EPS for the current fiscal year.
Insider Buying and Selling
In other ALX Oncology news, CEO Jason Lettmann bought 71,163 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were acquired at an average price of $1.08 per share, with a total value of $76,856.04. Following the transaction, the chief executive officer owned 305,121 shares of the company's stock, valued at approximately $329,530.68. This trade represents a 30.42% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 21.00% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Almitas Capital LLC increased its position in ALX Oncology by 10.6% during the 1st quarter. Almitas Capital LLC now owns 1,353,141 shares of the company's stock valued at $843,000 after purchasing an additional 130,196 shares during the period. Acadian Asset Management LLC grew its position in shares of ALX Oncology by 16.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company's stock worth $806,000 after buying an additional 186,883 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ALX Oncology in the 2nd quarter worth approximately $84,000. Nuveen LLC purchased a new position in shares of ALX Oncology in the 1st quarter worth approximately $103,000. Finally, AQR Capital Management LLC grew its position in shares of ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company's stock worth $74,000 after buying an additional 77,065 shares during the last quarter. Hedge funds and other institutional investors own 97.97% of the company's stock.
About ALX Oncology
(
Get Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ALX Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALX Oncology wasn't on the list.
While ALX Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
